376 related articles for article (PubMed ID: 12815232)
1. Antibodies that recognize bisected complex N-glycans on cell surface glycoproteins can be made in mice lacking N-acetylglucosaminyltransferase III.
Lee J; Park SH; Stanley P
Glycoconj J; 2002 Mar; 19(3):211-9. PubMed ID: 12815232
[TBL] [Abstract][Full Text] [Related]
2. Molecular analysis of three gain-of-function CHO mutants that add the bisecting GlcNAc to N-glycans.
Stanley P; Sundaram S; Tang J; Shi S
Glycobiology; 2005 Jan; 15(1):43-53. PubMed ID: 15329358
[TBL] [Abstract][Full Text] [Related]
3. Truncated, inactive N-acetylglucosaminyltransferase III (GlcNAc-TIII) induces neurological and other traits absent in mice that lack GlcNAc-TIII.
Bhattacharyya R; Bhaumik M; Raju TS; Stanley P
J Biol Chem; 2002 Jul; 277(29):26300-9. PubMed ID: 11986323
[TBL] [Abstract][Full Text] [Related]
4. Isolation, characterization and inactivation of the mouse Mgat3 gene: the bisecting N-acetylglucosamine in asparagine-linked oligosaccharides appears dispensable for viability and reproduction.
Priatel JJ; Sarkar M; Schachter H; Marth JD
Glycobiology; 1997 Feb; 7(1):45-56. PubMed ID: 9061364
[TBL] [Abstract][Full Text] [Related]
5. A subclass of cell surface carbohydrates revealed by a CHO mutant with two glycosylation mutations.
Stanley P; Sundaram S; Sallustio S
Glycobiology; 1991 Jun; 1(3):307-14. PubMed ID: 1838951
[TBL] [Abstract][Full Text] [Related]
6. Biological consequences of overexpressing or eliminating N-acetylglucosaminyltransferase-TIII in the mouse.
Stanley P
Biochim Biophys Acta; 2002 Dec; 1573(3):363-8. PubMed ID: 12417419
[TBL] [Abstract][Full Text] [Related]
7. Cloning and chromosomal mapping of the mouse Mgat3 gene encoding N-acetylglucosaminyltransferase III.
Bhaumik M; Seldin MF; Stanley P
Gene; 1995 Oct; 164(2):295-300. PubMed ID: 7590346
[TBL] [Abstract][Full Text] [Related]
8. Efficient introduction of a bisecting GlcNAc residue in tobacco N-glycans by expression of the gene encoding human N-acetylglucosaminyltransferase III.
Rouwendal GJ; Wuhrer M; Florack DE; Koeleman CA; Deelder AM; Bakker H; Stoopen GM; van Die I; Helsper JP; Hokke CH; Bosch D
Glycobiology; 2007 Mar; 17(3):334-44. PubMed ID: 17179169
[TBL] [Abstract][Full Text] [Related]
9. Progression of hepatic neoplasms is severely retarded in mice lacking the bisecting N-acetylglucosamine on N-glycans: evidence for a glycoprotein factor that facilitates hepatic tumor progression.
Bhaumik M; Harris T; Sundaram S; Johnson L; Guttenplan J; Rogler C; Stanley P
Cancer Res; 1998 Jul; 58(13):2881-7. PubMed ID: 9661906
[TBL] [Abstract][Full Text] [Related]
10. The bisecting GlcNAc on N-glycans inhibits growth factor signaling and retards mammary tumor progression.
Song Y; Aglipay JA; Bernstein JD; Goswami S; Stanley P
Cancer Res; 2010 Apr; 70(8):3361-71. PubMed ID: 20395209
[TBL] [Abstract][Full Text] [Related]
11. The bisecting GlcNAc in cell growth control and tumor progression.
Miwa HE; Song Y; Alvarez R; Cummings RD; Stanley P
Glycoconj J; 2012 Dec; 29(8-9):609-18. PubMed ID: 22476631
[TBL] [Abstract][Full Text] [Related]
12. Peptide Sequence Mapping around Bisecting GlcNAc-Bearing
Ohkawa Y; Kizuka Y; Takata M; Nakano M; Ito E; Mishra SK; Akatsuka H; Harada Y; Taniguchi N
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445285
[No Abstract] [Full Text] [Related]
13. New evidence for an extra-hepatic role of N-acetylglucosaminyltransferase III in the progression of diethylnitrosamine-induced liver tumors in mice.
Yang X; Bhaumik M; Bhattacharyya R; Gong S; Rogler CE; Stanley P
Cancer Res; 2000 Jun; 60(12):3313-9. PubMed ID: 10866326
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic activation of MGAT3 and corresponding bisecting GlcNAc shortens the survival of cancer patients.
Kohler RS; Anugraham M; López MN; Xiao C; Schoetzau A; Hettich T; Schlotterbeck G; Fedier A; Jacob F; Heinzelmann-Schwarz V
Oncotarget; 2016 Aug; 7(32):51674-51686. PubMed ID: 27429195
[TBL] [Abstract][Full Text] [Related]
15. Bisecting GlcNAc structures act as negative sorting signals for cell surface glycoproteins in forskolin-treated rat hepatoma cells.
Sultan AS; Miyoshi E; Ihara Y; Nishikawa A; Tsukada Y; Taniguchi N
J Biol Chem; 1997 Jan; 272(5):2866-72. PubMed ID: 9006930
[TBL] [Abstract][Full Text] [Related]
16. A dominant mutation to ricin resistance in Chinese hamster ovary cells induces UDP-GlcNAc:glycopeptide beta-4-N-acetylglucosaminyltransferase III activity.
Campbell C; Stanley P
J Biol Chem; 1984 Nov; 259(21):13370-8. PubMed ID: 6238035
[TBL] [Abstract][Full Text] [Related]
17. Reduced hepatocyte proliferation is the basis of retarded liver tumor progression and liver regeneration in mice lacking N-acetylglucosaminyltransferase III.
Yang X; Tang J; Rogler CE; Stanley P
Cancer Res; 2003 Nov; 63(22):7753-9. PubMed ID: 14633700
[TBL] [Abstract][Full Text] [Related]
18. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro.
Hodoniczky J; Zheng YZ; James DC
Biotechnol Prog; 2005; 21(6):1644-52. PubMed ID: 16321047
[TBL] [Abstract][Full Text] [Related]
19. Antibodies that detect O-linked β-D-N-acetylglucosamine on the extracellular domain of cell surface glycoproteins.
Tashima Y; Stanley P
J Biol Chem; 2014 Apr; 289(16):11132-11142. PubMed ID: 24573683
[TBL] [Abstract][Full Text] [Related]
20. Glycoproteomic analysis reveals the effects of bisecting GlcNAc in intrahepatic cholangiocarcinoma.
Dan W; Li C; Li J; Li P; Xin M; Chen Z; Dang L; Yu Z; Li J; Shen J; Hu L; Sun S
Glycoconj J; 2022 Dec; 39(6):737-745. PubMed ID: 36322335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
